Asciminib and ponatinib combination in Philadelphia chromosome-positive acute lymphoblastic leukemia

Since the development of tyrosine kinase inhibitors (TKIs) targeting BCR/ABL1 and significantly improved outcomes on long-term disease-free survival in Philadelphia chromosome–positive (Ph+) acute ...